UroGen Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell UroGen Pharma and other ETFs, options, and stocks.

About URGN

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. 

CEO
Elizabeth Barrett
CEOElizabeth Barrett
Employees
291
Employees291
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
2004
Founded2004
Employees
291
Employees291

URGN Key Statistics

Market cap
2.71B
Market cap2.71B
Price-Earnings ratio
-23.55
Price-Earnings ratio-23.55
Dividend yield
Dividend yield
Average volume
924.30K
Average volume924.30K
High today
$48.19
High today$48.19
Low today
$45.70
Low today$45.70
Open price
$47.23
Open price$47.23
Volume
1.03M
Volume1.03M
52 Week high
$48.19
52 Week high$48.19
52 Week low
$15.86
52 Week low$15.86

Stock Snapshot

As of today, UroGen Pharma(URGN) shares are valued at $46.96. The company's market cap stands at 2.71B, with a P/E ratio of -23.55.

As of 2026-08-09, UroGen Pharma(URGN) stock has fluctuated between $45.70 and $48.19. The current price stands at $46.96, placing the stock +2.8% above today's low and -2.6% off the high.

UroGen Pharma(URGN) shares are trading with a volume of 1.03M, against a daily average of 924.3K.

During the past year, UroGen Pharma(URGN) stock moved between $15.86 at its lowest and $48.19 at its peak.

During the past year, UroGen Pharma(URGN) stock moved between $15.86 at its lowest and $48.19 at its peak.

URGN News

Simply Wall St 1d
UroGen Pharma Stock Looks Fairly Priced Despite Its 210% Run - simplywall.st

...

UroGen Pharma Stock Looks Fairly Priced Despite Its 210% Run - simplywall.st
Nasdaq 3d
UroGen Pharma Reaches Analyst Target Price

In recent trading, shares of UroGen Pharma Ltd (Symbol: URGN) have crossed above the average analyst 12-month target price of $44.75, changing hands for $46.43/...

UroGen Pharma Reaches Analyst Target Price
Simply Wall St 4d
UroGen Pharma Stock Jumps As Revenue Surge Outruns Loss Concerns

UroGen Pharma stock rose 16.3% to US$46.43 on the first trading day after earnings, a sharp move for a company still carrying material losses. The market is rea...

UroGen Pharma Stock Jumps As Revenue Surge Outruns Loss Concerns

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own URGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.